US Patent

US11466004 — Solid forms of an FGFR inhibitor and processes for preparing the same

Method of Use · Assigned to Incyte Corp · Expires 2039-05-03 · 13y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects solid forms and methods of preparing a specific compound useful in treating FGFR-associated or mediated diseases, such as cancer.

USPTO Abstract

The present disclosure relates to 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3â²,2â²:5,6]pyrido[4,3-d]pyrimidin-2-one, solid forms and polymorphs thereof, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.

Drugs covered by this patent

Pemazyre (PEMIGATINIB) · Incyte Corp

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3464`	—	Pemazyre
`U-3464`	—	Pemazyre
`U-3464`	—	Pemazyre

Patent Metadata

Patent number: US11466004
Jurisdiction: US
Classification: Method of Use
Expires: 2039-05-03
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.